Table 1.
In vitro cytotoxicity of newly synthesized targets (IVa–n) with IC50 in µM
| Comp. | Ar | IC50 values, µM | |||
|---|---|---|---|---|---|
| [c]HeLa | [d]MCF-7 | [e]HEK 293T | [f]A549 | ||
| (IVa) | C6H5 | 3.89 ± 0.45 | 4.76 ± 1.23 | 3.92 ± 0.60 | 5.78 ± 0.76 |
| (IVb) | 3-CH3C6H4, | 3.40 ± 0.13 | 4.27 ± 1.32 | 3.72 ± 1.58 | 5.45 ± 1.63 |
| (IVc) | 4-ClC6H4 | 17.76 ± 1.28 | 15.75 ± 1.40 | 18.00 ± 2.18 | ND |
| (IVd) | 4-BrC6H4 | 3.20 ± 1.32 | 4.19 ± 1.87 | 3.59 ± 1.34 | 5.29 ± 1.34 |
| (IVe) | 4-FC6H4 | 18.11 ± 2.10 | 19.86 ± 2.69 | 18.63 ± 1.61 | 16.13 ± 1.21 |
| (IVf) | 4-CNC6H4 | 18.97 ± 2.48 | 17.82 ± 2.86 | 17.47 ± 2.50 | 16.12 ± 1.23 |
| (IVg) | 3,5-di-ClC6H3 | 16.12 ± 1.27 | 16.02 ± 1.49 | 18.22 ± 2.26 | 16.22 ± 1.36 |
| (IVh) | 3,5-di-OCH3C6H3 | 7.25 ± 0.95 | 7.14 ± 0.71 | 8.78 ± 1.72 | 8.34 ± 1.52 |
| (IVi) | 4-NO2C6H4 | 5.13 ± 1.85 | 6.34 ± 0.40 | 5.78 ± 1.19 | 6.09 ± 1.21 |
| (IVj) | 4-CF3C6H4 | 14.22 ± 2.19 | 16.03 ± 2.18 | 17.89 ± 2.38 | 15.19 ± 1.32 |
| (IVk) | 3-OCH3C6H4 | ND | 18.28 ± 2.59 | ND | 17.12 ± 1.22 |
| (IVl) | 3,5-di-CH3 C6H3 | 16.01 ± 2.56 | 17.10 ± 2.45 | ND | 15.02 ± 1.04 |
| (IVm) | 3-NO2C6H4 | 17.12 ± 1.27 | 17.02 ± 3.49 | 15.30 ± 3.26 | 16.13 ± 1.24 |
| (IVn) | 2-CH3C6H4 | 16.23 ± 2.17 | 18.23 ± 2.49 | 16.12 ± 3.26 | 17.45 ± 1.36 |
| Doxorubicin | 3.18 ± 1.02 | 4.13 ± 1.23 | 3.56 ± 2.17 | 5.23 ± 2.02 | |
ND = Not determine; [a] Each data represents as mean ± S.D. values; [b] From three different experiments performed in triplicates; [c] HeLa: human cervical cancer cell line; [d] MCF-7: human breast cancer cell line; [e] HEK 293T: embryonic kidneycancer cell line; [f] A549; human lung cancer cell line